ABSTRACT-To clarify the roles of dopamine D, and D2 receptors in behavioral symptoms of Parkinson's disease, antiparkinsonian effects of various dopamine agonists in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian monkeys were investigated with regard to induction of hyperactivity such as excitability, irritability and aggressiveness. The non-selective dopamine agonist apomorphine ameliorated the parkinsonism, but induced marked hyperactivity dose-dependently. Pretreatment with either the dopamine D, antagonist SCH 23390 or the dopamine D2 antagonist sulpiride markedly suppressed the apomorphine-induced hyperactivity with slight attenuation of the antiparkinsonian effects. Both the dopamine D2-receptor agonist quinpirole and the dopamine D,-receptor agonist SKF 82958 ameliorated the parkinsonism in a dose-dependent manner with a slight induction of hyperactivity. Combination treatment of a threshold dose of quinpirole with that of SKF 82958 augmented the antiparkinsonian effects without a marked induction of hyperactivity. However, the combination treatment at higher doses induced marked hyperactivity accompanied by augmented antiparkinsonian effects. These results suggest that stimulation of either central dopamine D, or D2 receptors is requisite for the antiparkinsonian effects and concurrent strong stimulation of both central dopamine D, and D2 receptors causes marked hyperactivity which may be predictive of dopaminergic psychiatric side effects.
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Central dopamine (DA) receptors may be classified into two subtypes (D, and D2) on the basis of structural homology, biochemical properties and pharmacological profiles, although five subtypes of dopamine receptors have recently been identified in various dopaminergic systems of mammalian brains (1, 2) . Steadily accumulating evidence indicates that under conditions, concurrent stimulation of both dopamine D, and D2 receptors is required for the manifestation of behavioral or electrophysiological effects in rodents (3), although opposite effects of dopamine D, and D2 agonists on some of oral movements is observed in rats (4) . However, the specific roles of these receptors and their interaction in the pathophysiology of Parkinson's disease remains uncharacterized. To date, various direct dopamine D2-receptor agonists such as bromocriptine and lisuride have been evaluated in clinical trials (5, 6) . These clinical trials demonstrated that monotherapy with the dopamine D2-receptor agonist is effective but insufficient to produce an adequate therapeutic response in patients with Parkinson's disease compared to levodopa (L-DOPA) therapy, suggesting that stimulation of dopamine D2 receptors is essential, but dopamine D, receptors also may play a pivotal role in the treatment of Parkinson's disease. However, the role of dopamine D, receptors has not been clearly determined.
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys, the partial dopamine D,-receptor agonist SKF 38393 failed to ameliorate the parkinsonism (7) and suppressed the antiparkinsonian effects of the dopamine D2-agonist quinpirole (8) . On the other hand, the another partial dopamine D,-receptor agonist CY 208-243 ameliorated the parkinsonism and potentiated the antiparkinsonian effect elicited by bromocriptine (9, 10). Recently full dopamine D,-receptor agonists such as dihydrexidine and SKF 81297 have been reported to show an antiparkinsonian effect (11, 12) .
L-DOPA, the direct precursor of dopamine, is still the most effective drug for the treatment of motor dysfunction in Parkinson's disease, but has been noticed to induce psychiatric side effects, including delusion, hallucination and organic confusional states, and motor complications such as daily fluctuations in motor capability and dyskinesia (13) . Although the cause of these psychiatric side effects in the L-DOPA therapy remains insufficiently characterized, the concurrent stimulation of dopamine D1-and D2-receptor subtypes is believed to result in some of these side effects.
The present study was performed to clarify the behavioral roles and interactions between dopamine D1 and D2 receptors in Parkinson's disease. We investigated the behavioral effects of various dopamine agonists, the nonselective dopamine agonist apomorphine, the dopamine D1-receptor agonist SKF 82958 (14) and the dopamine D2-receptor agonist quinpirole in MPTP-lesioned parkinsonian cynomolgus monkeys, with regard to the induction of hyperactivity such as excitability, irritability and aggressiveness.
MATERIALS AND METHODS

Animal preparation
In six cynomolgus monkeys (Macaca fascicularis; Clea Japan, Inc., Tokyo), three intravenous injections of 0.3 mg/kg of MPTP hydrochloride (Research Biochemicals, Inc. (RBI), Natick, MA, USA) were given at intervals of 3-4 days. This treatment was followed by several injections of the same dosage every 7 days. The animals showed persistent parkinsonian symptoms when the total cumulative dose reached 1.5 to 2.1 mg/kg. In the experiment with apomorphine treatment, four animals weighing 3.3 to 4.8 kg with persistent parkinsonism were used about 1 year after the latest MPTP injection. After that experiment, one animal died and two animals were added for the other experiments (finally, five animals weighing 3.3 to 5.2 kg).
Behavioral assessment
Parkinsonism and hyperactivity (irritability, excitability and aggressiveness) were scored by the rating scale illustrated in Table 1 according to Clarke et al. (15) with a slight modification. Behavioral assessments with this scoring scale were carried out by an examiner (T.A.) who was unaware of to the treatment conditions. A washout period of at least 3 days elapsed between drug treatments.
Drug administration
Apomorphine hydrochloride (Sigma, St. Louis, MO, USA) was dissolved into saline solution containing 0.05010 ascorbic acid. Quinpirole hydrochloride (RBI), SKF 82958 (RBI) and SCH 23390 (RBI) were dissolved into saline solution. SCH 23390 and sulpiride (Dogmatyl Injection; Fujisawa Pharmaceuticals Co., Ltd., Osaka) were administered 15 and 90 min, respectively, prior to the injection of apomorphine. In the combination study with quinpirole and SKF 82958, quinpirole were administered 15 min prior to the injection of SKF 82958. All drugs were administered subcutaneously with an injection volume of 0.1 ml/kg, except for sulpiride which was administered in an appropriate volume at the concentration of 50 mg/ml.
Statistics
Statistical differences were determined by two-way repeated measures analysis of variance (ANOVA) and followed by Dunnett's tests for multiple comparisons where appropriate. A probability within 0.05 was considered to indicate a significant difference.
RESULTS
The non-selective dopamine-receptor agonist apomorphine (0.01 -0.3 mg/kg, s.c.) ameliorated dose-dependently the symptoms of parkinsonism such as tremor and bradykinesia, and it simultaneously induced marked hyperactivity such as excitability, irritability and aggressiveness ( Fig. 1) . The hyperactivity disappeared when the parkinsonism was re-established within 2 hr (data not shown).
The selective dopamine D2-receptor antagonist sulpiride (100 mg/kg, s. Both the selective full dopamine D2-receptor agonist quinpirole (0.03-0.3 mg/kg, s.c.) and the selective full dopamine D1-receptor agonist SKF 82958 (0.1-0.5 mg/kg, s.c.) ameliorated the symptoms of parkinsonism such as tremor and bradykinesia dose-dependently with a slight induction of hyperactivity. The antiparkinsonian effects of quinpirole at 0.3 mg/kg, s.c. lasted more than 3 hr (Fig. 4) . The antiparkinsonian effects of SKF 82958 at 0.5 mg/kg, s.c. disappeared within 1.5 hr (Fig. 5 ).
Combination treatment with threshold doses of quinpirole (0.01 mg/kg, s.c.) and that of SKF 82958 (0.1 mg/kg, s.c.) augmented the antiparkinsonian effects without induction of any hyperactivity. The augmented antiparkinsonian effect by combined treatment with quinpirole and SKF 82958 disappeared within 1 hr after the administration of SKF 82958 (Fig. 6) . The combination treatment with higher doses of quinpirole (0.1 mg/kg, s.c.) and SKF 82958 (0.25 mg/kg, s.c.), at which they showed potent antiparkinsonian effects by themselves, induced marked hyperactivity transiently and augmented the antiparkinsonian effects. The hyperactivity induced by the combination treatment disappeared within 30 min. The time course of the appearance of the hyperactivity was almost identical to that of the antiparkinsonian effects by SKF 82958 (Fig. 7) .
DISCUSSION
In the present study, both the selective dopamine D1-and D2-receptor antagonists at the doses tested failed to suppress the antiparkinsonian effects by the non-selective dopamine D1/D2-receptor agonist apomorphine. Furthermore, the selective dopamine D1-receptor agonist SKF 82958 with full agonistic activity as well as the dopamine D2-receptor agonist quinpirole showed the antiparkinsonian effects. These results are consistent with the previous reports that the selective dopamine D1-receptor agonists with full agonistic activity such as dihydrexidine and SKF 81297 ameliorate the parkinsonism in MPTP-lesioned monkeys (11, 12) . These findings together with the present results indicate that a sufficient stimulation of dopamine D1-receptors, as well as that of dopamine D2 receptors, ameliorates the symptoms of Parkinson's disease.
In contrast to apomorphine inducing the marked hyperactivity, either of the selective dopamine D1-or D2-receptor agonists alone did not induce marked hyperactivity with further increase in dose. Furthermore, both the selective dopamine D1-and the D2-receptor antagonists at the doses tested suppressed the induction of hyperactivity by apomorphine without marked attenuation of the antiparkinsonian effect. In addition, the combination treat- and D2 receptors. In MPTP-lesioned parkinsonian monkeys, the nigrostriatal dopamine neurons are selectively degenerated, which results in the dopamine depletion and the development of postsynaptic supersensitivity of dopamine receptors in the striatum, whereas MPTP causes less severe degeneration of the mesolimbic and cortical dopamine neurons (16) . Under normal conditions, concurrent stimulation of dopamine D, and D2 receptors has been reported to be required for the manifestation of some behavioral or electrophysiological effects (3). However, when the nigrostriatal pathway is disrupted, the actions of dopamine D, and D2 receptors seem to become independent (17) . Thus, in MPTP-lesioned parkinsonian monkeys, it can be postulated that some behaviors via mesolimbic/cortical dopamine neurons require concurrent stimulation of dopamine D, and D2 receptors, whereas those via nigrostriatal dopamine neurons can be elicited by independent stimulation of either dopamine D, or D2 receptors. Admittedly, animal studies do not dispose of reliable models of psychotic disorders. Pharmacogenic psychoses induced in the animal are evaluated on the basis of complex and bizarre psychomotor symptoms, which may or may not reflect psychomotor abnormality manifested in humans (18) . It should be noted, however, that, in contrast to psychosis in schizophrenia, human pharmacogenic psychoses are induced by a particular group of drugs with a common mechanism of action (e.g., dopamine receptor activation) and confined to a particular subpopulation of neurological disorders (e.g., advanced Parkinson's disease). Thus, pharmacogenic psychoses are more likely to be induced in an animal model, particularly if the model also mimics the pathophysiology of the underlying human disease as it does in the MPTP-induced parkinsonism in monkeys. If one hypothesizes that in MPTP-lesioned monkeys the dopamine agonist-induced hyperactivity (excitability, irritability and aggressiveness) in the present study represent animal experimental equivalents of psychotic side effects elicited in parkinsonian patients by dopamine substitution therapy, the results of the present studies suggest that the concurrent strong stimulation of both dopamine D1 and D2 receptors may be involved in the induction of some of the psychiatric side effects in pharmacotherapy with L-DOPA or apomorphine.
In the present study, the non-selective dopamine agonist apomorphine was suggested to have sufficient dopamine D, agonistic activity to ameliorate the symptoms of parkinsonism in the primate model under blockade of its D2 agonist action, in contrast to SKF 38393 which deteriorated the parkinsonism (7), although apomorphine has been reported to exhibit a partial dopamine D1 agonistic activity in the adenylate cyclase assay of rat striatal homogenates, like SKF 38393 (19) . These discrepancies may be due to following: The dopamine D1-receptor family, which is composed of DIA-and DIB-receptor subtypes, is coupled to the stimulation of adenylate cyclase, but the conventional assay for the adenylate cyclase can not detect differentially the intrinsic activity of some ligands on each subtype; and as a result, it is difficult at present to say whether apomorphine and SKF 38393 may act as a full or a partial agonist (possibly antagonist) to the DIAand DIB-receptor subtypes, although they may bind with a high affinity to both subtypes (2) . Thus, it can be assumed that apomorphine may be an agonist with a sufficient activity on the dopamine D1-receptor subtype essential for the amelioration of the parkinsonism in the primate model, while SKF 38393 may be an antagonist.
Five subtypes of central dopamine receptors have been identified as described in the introduction, but these can be classified into two major families of receptors: dopamine D, (D1A and DIB, also known as D, and D5, respectively) and dopamine D2 (D2A, D2B and D2C, also known as D2, D3 and D4, respectively). Apomorphine and quinpirole have been shown to act as full agonists towards the dopamine D2A-receptor subtype, while sulpiride acts as an antagonist (20) ; and they also bind with a high affiniy to the dopamine D2B and D2C receptor, although it remains unclarified whether they may act as an agonist or an antagonist towards the dopamine D2B-and D2C-receptor subtypes (21, 22) . Moreover, the dopamine D2B and D2C receptors were considered to be involved in psychiatric symptoms in schizophrenic patients, because they were found to be rich in the mesolimbic and cortical areas of the brain, and the atypical neuroleptics such as clozapine and sulpiride bind with a high affinity to these receptors. On the other hand, the dopamine DIA-and D1B-receptor subtypes have not been well investigated, because no drug with a selectivity to each receptor subtype has been developed. Thus, the present findings can be interpreted to indicate that concurrent stimulation of D2B or D2C receptors and D1 receptors such as DIA and D1B receptors might be involved in the induction of hyperactivity.
In conclusion, our findings suggest that stimulation of either central dopamine D1 or dopamine D2 receptors is requisite for the antiparkinsonian effects, and concurrent strong stimulation of both central dopamine D1 and dopamine D2 receptors causes marked hyperactivity that may be predictive of dopaminergic psychiatric side effects.
